Publications by authors named "C S Lesser"
Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.
Microb Biotechnol
November 2024
Live biotherapeutic products (LBPs), including engineered bacteria, are rapidly emerging as potential therapeutic interventions. These innovative therapies can serve as live in situ drug delivery platforms for the direct deposition of therapeutic payloads, including complex biologics, at sites of disease. This approach offers a platform likely to enhance therapeutic efficacy and decrease off-target side effects.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how 35 nuclear receptors (NRs) influence the differentiation and maintenance of key immune cells using a method called "Rainbow-CRISPR."
- It finds that receptors for retinoic acid have significant and specific roles in various immune cell types, particularly in macrophages.
- Notably, it uncovers a unique function of the retinoic acid receptor gamma (RARγ) in regulating immune cell survival and inflammasome activity, revealing its dual role in promoting health or cell death in macrophages.
Article Synopsis
- Many pathogenic bacteria possess plasmids that encode virulence factors, essential for their ability to infect and colonize hosts, but the regulation of these plasmids is not well understood.
- The study focuses on the type III secretion system (T3SS), crucial for human pathogenic bacteria, and reveals that its expression is influenced by the plasmid copy number, which increases with temperature, aiding in bacterial virulence.
- The chromosomal gene encoding polyadenylase PAP I is vital for controlling plasmid copy number, maintaining plasmid stability, and enhancing antibiotic resistance, highlighting its role in the regulation of virulence and antimicrobial resistance plasmids in bacteria.
Engineered smart microbes that deliver therapeutic payloads are emerging as treatment modalities, particularly for diseases with links to the gastrointestinal tract. Enterohemorrhagic (EHEC) is a causative agent of potentially lethal hemolytic uremic syndrome. Given concerns that antibiotic treatment increases EHEC production of Shiga toxin (Stx), which is responsible for systemic disease, novel remedies are needed.
View Article and Find Full Text PDFBackground: Mesenteric adipose tissue (mAT) hyperplasia, known as creeping fat, is a pathologic characteristic of Crohn's disease (CD). In our previously reported cohort, we observed that Achromobacter pulmonis was the most abundant and prevalent bacteria cultivated from creeping fat.
Methods: A whole genomic sequencing and identification of T3SS orthologs of mAT-derived A.